Rapport Therapeutics Conference Call Summary Company Overview - Company: Rapport Therapeutics (NasdaqGM:RAPP) - Focus: Development of a novel drug for epilepsy treatment, specifically RAP-219, which is advancing from phase 2 to phase 3 trials [1][2] Core Points and Arguments Drug Mechanism and Efficacy - Target: RAP-219 is a TARP gamma-8 AMPA modulator, focusing on four brain structures to treat focal onset seizures and bipolar mania [3] - Efficacy: Preclinical models showed unprecedented efficacy in controlling seizures without significant adverse effects, unlike existing pan-AMPA antagonists [5][11] - Clinical Data: Phase 2 trial demonstrated a 78% median reduction in clinical seizures and a 72% reduction in electrographic seizures, surpassing initial expectations of 50% and 30% respectively [19][31] Safety Profile - Tolerability: The drug exhibited a low discontinuation rate of 10%, with all adverse events being mild to moderate, and no serious adverse events reported [21] - Therapeutic Index: The drug maintains a wide therapeutic index, which is crucial for its safety and efficacy [13] Trial Design and Execution - Phase 3 Trial: The design will include two parallel studies with approximately 330 subjects each, focusing on low-medium and mid-high dose strategies [24][25] - Global Collaboration: A partnership with Tenacia in China aims to enhance global development and patient enrollment for the phase 3 trials [27] Market Opportunity - Target Population: 30%-40% of the 1.8 million patients with focal onset seizures are refractory to current treatments, representing a significant market opportunity [30] - Market Size: The potential market for branded drugs in this segment is estimated at $15 billion [31] Additional Indications - Bipolar Mania: The drug is also being studied for bipolar mania, leveraging its mechanism to reduce glutamate transmission, which is implicated in the disorder [36][37] - Tonic-Clonic Seizures: Plans to initiate a phase 2 study for tonic-clonic seizures based on positive results from focal onset studies [39] Long-Acting Injectable Development - Differentiation: RAP-219 is being developed as a long-acting injectable (LAI), which is uncommon for anti-seizure medications. Its potency, low solubility, and long half-life make it suitable for this formulation [42][44] - Market Impact: The LAI could extend exclusivity and revenue durability, appealing to both patients and physicians [47] Conclusion - Rapport Therapeutics is positioned to make significant advancements in the treatment of epilepsy and bipolar disorder with its innovative drug RAP-219, backed by strong clinical data and a clear market strategy. The ongoing development of a long-acting injectable formulation further enhances its potential impact in the market [50]
Rapport Therapeutics (NasdaqGM:RAPP) 2026 Conference Transcript